Avalo Therapeutics Inc. (AVTX)
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $390.88M
- EPS (TTM)
- -$2.26
- Dividend yield
- None
- 52-week range
- 6.53 – 24.27
- Day range
- 6.61 – 7.03
- Volume / Avg
- 1.18M / 1.80M
- Beta
- —
- Shares outstanding
- 57.82M
52-week range
AVTX stock today
Avalo Therapeutics (AVTX) closed at $6.76 on Nov 20, up 0.15% (+$0.01), versus the S&P 500's 3.70% decline. Shares are 72.1% below their 52-week high of $24.27, set on May 7, 2026 and 3.5% above the 52-week low of $6.53, near the bottom of the past year's range. AVTX is down 62.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.1%.
Avalo Therapeutics has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Avalo Therapeutics
Company profileAvalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Garry A. Neil M.D.
- Headquarters
- Wayne, PA
- Employees
- 33
- IPO year
- 2015
- Website
- avalotx.com
Financial highlights
Full financialsIn fiscal 2025, Avalo Therapeutics generated $59,000 in revenue, down 86.6% from fiscal 2024, its first annual decline since 2024. Avalo Therapeutics reported a net loss of $78.3 million, compared with a loss of $35.1 million a year earlier. Operating margin was -123601.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $59.00K | $441.00K | $1.92M | $18.05M | $5.40M |
| Growth | -86.62% | -77.08% | -89.34% | +234.40% | -19.42% |
| Net income | $-78.26M | $-35.13M | $-31.54M | $-41.66M | $-84.38M |
| EPS (diluted) | $-5.84 | $-20.91 | $-113.58 | $-1,063.00 | — |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$34.80+414.79%
- Strong buy 2
- Buy 10
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.34 vs $-0.63
- Surprise
- +46.03%
AVTX news
All AVTX news- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Avalo Therapeutics, Inc. Enters $200,000,000 At-The-Market Offering Program and Terminates Prior AgreementNasdaq
- Avalo Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and $462.8 million in CashNasdaqAVTX, LEN.B
- Avalo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
Avalo Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OCSOculis Holding AG | 7.06 | -5.11% | $393.35M | vs AVTX |
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs AVTX |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs AVTX |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs AVTX |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs AVTX |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs AVTX |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs AVTX |
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs AVTX |
Indexes, lists and sector
Avalo Therapeutics stock FAQ
What is Avalo Therapeutics's stock price today?
AVTX last traded at $6.76 as of Nov 20, 4:00 PM EST, up 0.15% on the day. Prices are delayed at least 15 minutes.
Does Avalo Therapeutics pay a dividend?
No. Avalo Therapeutics does not currently pay a regular cash dividend.
Who is Avalo Therapeutics's CEO?
Dr. Garry A. Neil M.D. is the chief executive officer of Avalo Therapeutics Inc., which has about 33 employees.
Has AVTX ever split its stock?
Yes. The most recent AVTX stock split was a 1-for-240 split on Dec 29, 2023, one of 2 splits on record.
What is the AVTX 52-week high?
The 52-week high for AVTX is $24.27 and the 52-week low is $6.53. The stock is currently 72.1% below its high.